Código QR (código de barras bidimensional)

Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis

Abstract Introduction Lebrikizumab and dupilumab are monoclonal antibodies approved for treating moderate-to-severe atopic dermatitis (AD). Both have demonstrated efficacy and safety over the 16-week SOLOs and ADvocate trials. However, AD is a chronic and relapsing inflammatory disease, and the long...

Fuld beskrivelse

Na minha lista:
Principais autores: Kim Rand, Juan Manuel Ramos-Goñi, Bülent Akmaz, Laia Solé-Feu, José-Carlos Armario-Hita
Format: Artigo
Sprog:Inglês
Udgivet: Adis, Springer Healthcare 2023-10-01
Serier:Dermatology and Therapy
Fag:
Atopic dermatitis
Dupilumab
Eczema
Lebrikizumab
Matching-adjusted indirect comparison
Online adgang:https://doi.org/10.1007/s13555-023-01058-z
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker